
Essential Updates 2018/2019: Essential advances in surgical and adjuvant therapies for colorectal cancer
Author(s) -
Akagi Tomonori,
Inomata Masafumi
Publication year - 2020
Publication title -
annals of gastroenterological surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.308
H-Index - 15
ISSN - 2475-0328
DOI - 10.1002/ags3.12307
Subject(s) - medicine , colorectal cancer , oxaliplatin , dissection (medical) , adjuvant , chemotherapy , rectum , total mesorectal excision , adjuvant therapy , adjuvant chemotherapy , modalities , guideline , oncology , cancer , surgery , general surgery , pathology , breast cancer , social science , sociology
Surgical resection and adjuvant chemotherapy are the only treatment modalities for localized colorectal cancer that can obtain a “cure.” The goal in surgically treating primary colorectal cancer is complete tumor removal along with dissection of systematic D3 lymph nodes. Adjuvant treatment controls recurrence and improves the prognosis of patients after they undergo R0 resection. Various clinical studies have promoted the gradual spread and clinical use of new surgical approaches such as laparoscopic surgery, robotic surgery, and transanal total mesorectal excision (TaTME). Additionally, the significance of adjuvant chemotherapy has been established and it is now recommended in the JSCCR (the Japanese Society for Cancer of the Colon and Rectum) guideline as a standard treatment. Herein, we review and summarize current surgical treatment and adjuvant chemotherapy for localized colorectal cancer and discuss recent advances in personalized medicine related to adjuvant chemotherapy.